Tyme, Inc. Appoints Giuseppe Del Priore, MD, MPH to Medical Advisory Board

NEW YORK--(BUSINESS WIRE)--Tyme, Inc. (OTC QB: TYMI), a research and development company focused on developing drug candidates for the treatment of cancer, has appointed Giuseppe Del Priore, MD, MPH to serve on its Medical Advisory Board. Dr. Del Priore, a renowned gynecologic oncologist, researcher and teacher, is the National Director of Gynecologic Oncology and Southeastern Regional Director at Cancer Treatment Centers of America.

"We are extremely pleased to welcome Dr. Del Priore to the Medical Advisory Board for Tyme"
"We are extremely pleased to welcome Dr. Del Priore to the Medical Advisory Board for Tyme," said CEO Steve Hoffman. "He is a true leader in the field of oncology and we look forward to benefitting from his guidance and expertise as we take our therapies to the next stage of clinical development."

Dr. Del Priore added, "Joining the Medical Advisory Board for Tyme is very exciting. I believe Tyme has tremendous potential to one day provide innovative oncology treatments for patients and I look forward to providing support and guidance to the company as it progresses its clinical programs."

Dr. Del Priore joined Cancer Treatment Centers of America (CTCA) as its National Director of Gynecologic Oncology. He also serves as the Southeastern Regional Director. Prior to CTCA, Dr. Del Priore was Professor and Director of Gynecologic Oncology at the Indiana University School of Medicine in Indianapolis, where he directed its gynecologic oncology fellowship program and continues to teach. He previously also served as Director of Gynecologic Oncology at New York Downtown Hospital, Montefiore Medical Center, and Bellevue Hospital in New York City, as well as Assistant Director of Gynecologic Oncology at New York University School of Medicine.

Dr. Del Priore earned his Doctor of Medicine with Distinction in Research from State University of New York Downstate Medical Center in Brooklyn. He studied at The City University of New York's Brooklyn College in a combined Bachelor of Arts/Doctor of Medicine Program, earning both degrees in seven years. Dr. Del Priore graduated magna cum laude with a Bachelor of Arts in Philosophy and was valedictorian of his medical school class. He received his Master of Public Health in Biostatistics and Epidemiology from the University of Illinois at Chicago and completed other training at Northwestern University and the University of Rochester.

U.S. News and World Report named Dr. Del Priore one of its "Best Doctors" in 2011 and 2012. He is an active researcher and prolific writer. He has authored and published more than 170 papers, book chapters and abstracts and written three books.

Dr. Del Priore has received two patents and has others pending. He has served on several committees and organizations, including current appointments at the Society of Gynecologic Oncologists; and previously the Gynecologic Oncology Group, a National Cancer Institute Cooperative Group. He is also an examiner for the American Osteopathic Association Board of Obstetrics and Gynecology, Gyn Oncology subspecialty section.

In his free time, Dr. Del Priore has given back to his community by serving as a volunteer physician as part of the National Association of Free and Charitable Clinics; a volunteer firefighter in Westchester County, New York; an auxiliary police officer with the New York Police Department; and a volunteer ambulance driver with the Bay Ridge Ambulance Volunteer Organization.

About Tyme

Tyme is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic characteristics of cancer cells as well as activating the endogenous immune response against tumors. Tyme's approach is hypothesized to permit selective elimination of cancer cells, while simultaneously improving patients' well-being, particularly with respect to pain severity and functional independence.

Tyme is currently developing for use in humans SM-88, a proprietary compound, which the company believes to be a first-in-class drug that harnesses the body's own immune defenses to fight tumor cells. SM-88 is a novel combination drug that synergistically target the unique metabolic features of cancer cells, thus providing a selective method of altering the susceptibility of cancer cells to oxidative stress. Tyme has completed a proof-of-concept clinical study for SM-88 in late-stage cancer patients with relapsed or highly refractory disease and is working towards submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration, with the goal of beginning a randomized clinical trial in multiple U.S. centers in the near future. Tyme anticipates an IND submission to the FDA in mid-2015.

For more information, visit our website: www.tymetechnologiesinc.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the company's actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned "Risk Factors" of Tyme's Current Report on Form 8-K/A filed with the US Securities and Exchange Commission on April 16, 2015 (available at www.sec.gov).

Readers can identify forward-looking statements by terms such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements, and forward-looking statements within this press release include statements regarding our drug development strategies, clinical trials and plans for submitting an IND with the FDA. Forward-looking statements reflect Tyme Technologies' current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, readers should not place undue reliance on these forward-looking statements.


Tyme, Inc.
Raghuram Selvaraju, Investor Relations
[email protected]
Media Contact:
Sam Brown, Inc.
Mike Beyer, 312-961-2502
[email protected]